Literature DB >> 16504680

Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation.

K Falkiewicz1, D Kamińska, W Nahaczewska, M Boratyńska, H Owczarek, M Klinger, M Woźniak, D Patrzałek, P Szyber.   

Abstract

The aim of the study was to assess impaired tubular phosphate reabsorption and renal function among patients on cyclosporine- or tacrolimus-based immunosuppression for 2 years after kidney transplantation. Among 60 cadaveric kidney allograft recipients observed for 48 months, 40 received cyclosporine, azathioprine, and prednisone (group A and B). Group C consisted of 20 patients receiving tacrolimus with steroid withdrawal at 3 months after transplantation. Renal function and calcium-phosphate metabolism-iPTH, 25-OHD, 1,25(OH)(2)D concentration, phosphate reabsorption (TRP; mmol/L), and tubular maximum phosphate reabsorption per glomerular filtration rate (TmPO(4)/GFR; mmol/L)-were assessed at 1, 6, 12, 18, and 24 months (groups A and C) or 24, 30, 36, 42, and 48 months (group B). Renal function after 24 months of observation was significantly better among tacrolimus-treated patients (serum creatinine concentration mumol/L; C: 94.6 +/- 16.8 vs A: 110.5 +/- 22.1 vs B: 121.1 +/- 30.9; P < .05). Among tacrolimus-treated recipients, TRP and TmPO(4)/GFR remained within normal values during the whole observation period. In groups A and B, TRP improved during the first year of observation; after 2 years it reached values observed in group C (TRP: A: 0.67 +/- 0.1; B: 0.72 +/- 0.13; C: 0.76 +/- 0.07; P = NS), whereas TmPO(4)/GFR remained low in group A after 2 years (A: 0.78 +/- 0.19; B: 0.91 +/- 0.25; C: 0.94 +/- 0.15; P < .05). Tacrolimus-treated patients exhibit significantly faster recovery from tubular phosphate reabsorption impairment compared with cyclosporine-treated recipients. Tacrolimus-based immunosuppression led to better kidney allograft function during 2-year observation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504680     DOI: 10.1016/j.transproceed.2005.12.083

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  A case of severe osteomalacia secondary to phosphate diabetes in a renal transplant recipient.

Authors:  Johnny Sayegh; Jean-François Augusto; Daniel Chappard; Paolo Insalaco; Jean-François Subra
Journal:  Int Urol Nephrol       Date:  2012-09-19       Impact factor: 2.370

2.  Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula.

Authors:  Eun Mi Yang; Sang Taek Lee; Hyun Jin Choi; Hee Yeon Cho; Joo Hoon Lee; Hee Gyung Kang; Young Seo Park; Hae Il Cheong; Il-Soo Ha
Journal:  World J Pediatr       Date:  2015-12-18       Impact factor: 2.764

Review 3.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

4.  Effects of 1α,25-dihydroxyvitamin D3 on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats.

Authors:  Dang-Khoa Vo; Thi-Thao-Linh Nguyen; Han-Joo Maeng
Journal:  J Pharm Investig       Date:  2022-03-10

5.  Electrolytes Disturbance and Cyclosporine Blood Levels among Kidney Transplant Recipients.

Authors:  B Einollahi; E Nemati; Z Rostami; M Teimoori; A R Ghadian
Journal:  Int J Organ Transplant Med       Date:  2012

6.  Complete remission induced by tacrolimus and low-dose prednisolone in adult minimal change nephrotic syndrome: A pilot study.

Authors:  Yong Chul Kim; Tae Woo Lee; Hajeong Lee; Ho Suk Koo; Kook-Hwan Oh; Kwon Wook Joo; Suhnggwon Kim; Ho Jun Chin
Journal:  Kidney Res Clin Pract       Date:  2012-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.